Head to Head Comparison: PTC Therapeutics (NASDAQ:PTCT) vs. Beam Therapeutics (NASDAQ:BEAM)

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Beam Therapeutics and PTC Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics 1 2 8 1 2.75
PTC Therapeutics 1 3 10 1 2.73

Beam Therapeutics currently has a consensus price target of $47.64, suggesting a potential upside of 126.73%. PTC Therapeutics has a consensus price target of $99.23, suggesting a potential upside of 64.75%. Given Beam Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Beam Therapeutics is more favorable than PTC Therapeutics.

Valuation and Earnings

This table compares Beam Therapeutics and PTC Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Beam Therapeutics $146.64 million 14.83 -$79.99 million ($1.04) -20.20
PTC Therapeutics $1.73 billion 2.91 $682.64 million ($1.40) -43.02

PTC Therapeutics has higher revenue and earnings than Beam Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Beam Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beam Therapeutics -73.04% -32.76% -25.80%
PTC Therapeutics -9.17% N/A -0.10%

Institutional and Insider Ownership

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Beam Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

About Beam Therapeutics

(Get Free Report)

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.